Ivermectin Orifarm

Ivermectin, the active ingredient in Ivermectin Orifarm, is an anthelmintic presented as an oral tablet for oral use. It treats a range of parasitic infections in humans, including onchocerciasis, strongyloidiasis, scabies, lymphatic filariasis and other helminth infections.

GNH USA supplies Ivermectin Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an antiparasitic agent used to treat infections caused by various helminths and ectoparasites. - Onchocerciasis: reduces microfilarial load and helps prevent disease progression. - Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection. - Scabies: eradicates the Sarcoptes scabiei mite, relieving itching and skin lesions. - Lymphatic filariasis: decreases adult worm burden and interrupts transmission. - Other helminth infections: provides broad‑spectrum activity against susceptible nematodes.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, usually transient. - Dizziness: occasional light‑headedness. - Pruritus: itching that may be related to parasite die‑off. - Fatigue: feeling of tiredness. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurological events: seizures, encephalopathy, or ataxia. - Hepatotoxicity: elevated liver enzymes or jaundice. - Hypersensitivity: anaphylaxis or angioedema. - Cardiac arrhythmias: rare conduction disturbances.

Before prescribing Ivermectin, consider patient‑specific factors and safety measures. - Pregnancy: use only if the potential benefit outweighs the risk, as safety data are limited. - Breastfeeding: weigh benefits against potential infant exposure through milk. - Liver impairment: monitor hepatic function and adjust therapy if needed. - Concomitant CNS depressants: observe for enhanced central nervous system effects. - Drug interactions: review all concurrent medications for potential interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ivermectin may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - CNS depressants (e.g., benzodiazepines): watch for additive sedation. - Other antiparasitics: assess cumulative toxicity risk.